Loading company…
SyneuRx develops therapeutics for mental health conditions and infectious diseases.
SyneuRx develops therapeutics for mental health conditions and infectious diseases, including treatments under clinical development for depression, schizophrenia, dementia, influenza and COVID-19. Its pipeline includes Pentarlandir®, ClozaBen and Synapsinae. Founded in 2013, the company is based in New Taipei, Taiwan, and led by CEO and founder Guochuan Tsai. In June 2021, it raised TWD 400 million in a PIPE from Taiwania Capital to fund clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in